San Francisco Business Times - by Steven E.F. Brown
Impax Laboratories Inc. said a drug it’s testing for use against Parkinson’s Disease did well in a mid-stage clinical trial.
The Hayward business (NASDAQ: IPXL), led by CEO Larry Hsu, makes generic drugs. It also has its own drug-making division, Impax Pharmaceuticals, led by President Michael Nestor, which is working on this drug.
This formulation of carbidopa-levdopa, IPX066, was tested against an existing carbidopa-levdopa drug called Sinemet, made by Merck & Co. (NYSE: MRK) and sold by Bristol-Myers Squibb Co. (NYSE: BMY). It performed better than Sinemet in this test, with the comparison being a measurement of “off” time reported by Parkinson’s patients during waking hours. IPX066 improved those symptoms for two hours longer in the test than Sinemet.
This Phase II trial enrolled 27 people with advanced Parkinson’s Disease. Impax is signing people up now for a Phase III test of the drug and plans another one early next year.
For more information go to www.parkinsonresearchfoundation.org
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment